Karyopharm Therapeutics
KPTI
KPTI
147 hedge funds and large institutions have $364M invested in Karyopharm Therapeutics in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 62 increasing their positions, 42 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
147
Holders Change
-2
Holders Change %
-1.34%
% of All Funds
2.54%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.02%
New
18
Increased
62
Reduced
42
Closed
20
Calls
$3.53M
Puts
$2.07M
Net Calls
+$1.46M
Net Calls Change
-$1.31M
Top Buyers
| 1 |
ABG
Ally Bridge Group
New York
|
$8.35M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
$8.26M |
| 3 |
Citadel Advisors
Miami,
Florida
|
$9.88M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
$4.64M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
$26.3M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
$49.2M |
| 2 |
Morgan Stanley
New York
|
$5.9M |
| 3 |
Walleye Capital
New York
|
$3.68M |
| 4 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
$0 |
| 5 |
Two Sigma Investments
New York
|
$1.25M |
